BUDESONIDE INHALER MARKET

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. BUDESONIDE INHALER MARKET Budesonide is a medication that is used to prevent symptoms of asthma. It is a corticosteroid or steroid (cortisone-like medicine). The medication prevents inflammation in the lungs to decrease the severity of asthma attack. Inhaled budesonide may be used with other asthma medicines such as bronchodilators, which are also used to open up narrowed breathing passages in the lungs. Budesonide is available in several forms such as powders, suspensions, and tablets. In powder form, the medication can be inhaled by mouth using an inhaler. It can also be used as suspension to inhale by mouth using a special jet nebulizer (machine that turns medication into a mist that can be inhaled). Some of the trade names under which budesonide is sold are Pulmicort, Rhinocort, and Entocort.  The global budesonide inhaler market size was valued at US$ 5.25 billion in 2017, and is expected to witness a CAGR of 5.8% over the forecast period (2018 – 2026). .

3. Global Budesonide Inhaler Market Share (%) Analysis, By Product Type, 2017 Source: Coherent Market Insights Analysis (2019)

4. Increasing number of launches in generic version of budesonide inhaler is expected to drive growth of the budesonide inhaler market Increasing number of launches in generic version of budesonide inhaler is a major driving factor for growth of the budesonide inhaler market growth. For instance, in 2016, Nephron Pharmaceuticals Corporation (Nephron) launched generic Budesonide Inhalation Suspension in the U.S. Nephron has licensed the Abbreviated New Drug Application from Apotex, Inc. The Budesonide Inhalation Suspension is the generic version of PulmicortRespules that is manufactured by AstraZeneca LP. Nephron will be responsible for the manufacturing, marketing, and distribution of Budesonide.

5. Budesonide Inhaler Market - Restraints The major restraining factor for budesonide inhaler market growth is the side effects shown by budesonide such as runny or stuffy nose, sneezing, coughing, sore throat, dry throat, nosebleed, nausea, vomiting, diarrhea, stomach pain, white patches or sores inside the mouth or on lips, headache, hoarseness, voice changes, or bad taste in the mouth. For instance, according to Product Monograph of PulmicortTurbuhaler from AstraZeneca Canada Inc. of 2017, side effects can be observed in 2 to 4% population who are under treatment of PulmicortTurbuhaler (budesonide). Some adverse effects include, respiratory infection, rhinitis, ear infection, otitis media, and viral infection, which can be observed in less than 3% population.

6. Budesonide Inhaler Market - Regional Insights On the basis of region, the global budesonide inhaler market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global budesonide inhaler market, owing to increasing regulatory approvals of budesonide inhaler. For instance, in November 2017, Cipla Ltd. received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the U.S. Food and Drug Administration (FDA) to market a generic version of AstraZeneca's PulmicortRespules. Asia Pacific is expected to foresee a rapid growth in the budesonide inhaler market during the forecast period. This is owing to presence of major companies such as Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Lunan Better Pharmaceutical, Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd. in emerging economies such as China, India, and Japan.

7. Global Budesonide Inhaler Market Share (%) Analysis, By Region, 2017 Source: Coherent Market Insights Analysis (2019)

8. Budesonide Inhaler Market - Competitive Landscape Key players operating in the global budesonide inhaler market include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., ChiesiFarmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

9. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. •  What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

10. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs

11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/